title: Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.
abstract: Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but higher susceptibilities to isavuconazole.
authors.affiliation: Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
authors.forename: K
authors.initials: K
authors.lastname: Datta
authors.forename: P
authors.initials: P
authors.lastname: Rhee
authors.forename: E
authors.initials: E
authors.lastname: Byrnes
authors.forename: G
authors.initials: G
authors.lastname: Garcia-Effron
authors.forename: D S
authors.initials: DS
authors.lastname: Perlin
authors.forename: J F
authors.initials: JF
authors.lastname: Staab
authors.forename: K A
authors.initials: KA
authors.lastname: Marr
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects* / Q000302:isolation & purification; D001393:Azoles / Q000494:pharmacology; D021821:Communicable Diseases, Emerging / Q000453:epidemiology / Q000382:microbiology*; D056285:Cryptococcus gattii / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000453:epidemiology / Q000382:microbiology*; D055326:Neosartorya / Q000187:drug effects* / Q000302:isolation & purification; D009570:Nitriles / Q000494:pharmacology*; D009656:North America; D011725:Pyridines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole